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Canagliflozin inhibits interleukin-
1β-stimulated cytokine and 
chemokine secretion in vascular 
endothelial cells by AMP-activated 
protein kinase-dependent and 
-independent mechanisms
Sarah J. Mancini1, Daria Boyd1, Omar J. Katwan1,2, Anastasiya Strembitska1,  
Tarek A. Almabrouk1,3, Simon Kennedy  1, Timothy M. Palmer4 & Ian P. Salt  1
Recent clinical trials of the hypoglycaemic sodium-glucose co-transporter-2 (SGLT2) inhibitors, which 
inhibit renal glucose reabsorption, have reported beneficial cardiovascular outcomes. Whether SGLT2 
inhibitors directly affect cardiovascular tissues, however, remains unclear. We have previously reported 
that the SGLT2 inhibitor canagliflozin activates AMP-activated protein kinase (AMPK) in immortalised 
cell lines and murine hepatocytes. As AMPK has anti-inflammatory actions in vascular cells, we 
examined whether SGLT2 inhibitors attenuated inflammatory signalling in cultured human endothelial 
cells. Incubation with clinically-relevant concentrations of canagliflozin, but not empagliflozin or 
dapagliflozin activated AMPK and inhibited IL-1β-stimulated adhesion of pro-monocytic U937 cells and 
secretion of IL-6 and monocyte chemoattractant protein-1 (MCP-1). Inhibition of MCP-1 secretion was 
attenuated by expression of dominant-negative AMPK and was mimicked by the direct AMPK activator, 
A769662. Stimulation of cells with either canagliflozin or A769662 had no effect on IL-1β-stimulated 
cell surface levels of adhesion molecules or nuclear factor-κB signalling. Despite these identical effects 
of canagliflozin and A769662, IL-1β-stimulated IL-6/MCP-1 mRNA was inhibited by canagliflozin, but 
not A769662, whereas IL-1β-stimulated c-jun N-terminal kinase phosphorylation was inhibited by 
A769662, but not canagliflozin. These data indicate that clinically-relevant canagliflozin concentrations 
directly inhibit endothelial pro-inflammatory chemokine/cytokine secretion by AMPK-dependent and 
-independent mechanisms without affecting early IL-1β signalling.
The development of vascular endothelial dysfunction, a key early step in atherogenesis, is associated with elevated 
circulating levels of interleukin (IL)-1β, tumour necrosis factor-α (TNFα) and IL-61. Indeed, recent phase clin-
ical 3 trials indicate that suppression of IL-1β signalling with the monoclonal antibody canakinumab markedly 
reduced the risk of major adverse cardiovascular events2, highlighting the important role of IL-1β in cardio-
vascular disease. IL-1β simultaneously activates nuclear factor-κB (NFκB) and c-jun N-terminal kinase (JNK) 
intracellular signalling pathways in cultured vascular endothelial cells, leading to activation of transcription factor 
complexes stimulating expression of other pro-inflammatory cytokines such as IL-6, adhesion molecules includ-
ing intercellular cell adhesion molecule-1 (ICAM-1) and the chemokine MCP-1 (monocyte chemoattractant 
protein-1)3,4. The increased expression of adhesion molecules, chemokines and cytokines recruits circulating 
leukocytes to the vascular wall, which subsequently differentiate into macrophages and accumulate modified low 
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density lipoproteins, leading to foam cell and atherosclerotic plaque formation1,4. IL-1β-stimulated NFκB and 
JNK activation occurs via a complex signalling mechanism, by which IL-1β binding to the IL-1 receptor stimu-
lates formation of a signalosome including TGFβ-activated kinase-1 (TAK1) and inhibitor of NFκB (IκB) kinase 
(IKK) in a manner dependent on IL-1 receptor associated kinases (IRAKs)4,5. TAK1 stimulation leads to phos-
phorylation and activation of mitogen-activated protein kinase kinases (MKK4 and MKK7) which phosphorylate 
and activate JNK5,6. In parallel, activated IKK phosphorylates IκBα, targeting it for proteasomal degradation and 
releasing active NFκB dimers4,5. Activated JNK phosphorylates nuclear transcription factor complex compo-
nents, including c-Jun, JunD and ATF-2 whereas NFκB heterodimers translocate into the nucleus and bind the 
promoters of target genes, leading to increased expression of pro-inflammatory cytokines, adhesion molecules 
and chemokines. Identification of novel inhibitory mechanisms that may alleviate the pro-inflammatory actions 
of IL-1β that contribute to atherogenesis is therefore important for potential new therapeutic strategies.
Inhibitors of sodium-glucose co-transporter 2 (SGLT2) are oral hypoglycaemic agents that act to reduce renal 
glucose reabsorption, thereby increasing glycosuria and reducing hyperglycaemia7. Intriguingly, large trials of 
the SGLT2 inhibitors empagliflozin and canagliflozin in people with type 2 diabetes at high risk of cardiovascular 
disease have identified that they convey significant improvements in blood pressure, body weight and cardiovas-
cular risk relative to placebo8,9. The cardiovascular actions of SGLT2 inhibitors may not be entirely explained by 
differences in glycaemia, suggesting other mechanisms may be involved7,10–12. Recent studies have reported that 
administration of SGLT2 inhibitors reduce atheroma burden in atherosclerosis-prone mouse models13,14. In addi-
tion, several recent studies have reported that administration of SGLT2 inhibitors improves pro-inflammatory 
IL-6, MCP-1 and ICAM-1 gene expression in blood vessels of rodent models of diabetes13,15–17. These vascular 
effects of systemic SGLT2 inhibitor administration may be secondary to changes in glycaemia, blood pressure or 
actions on extra-cardiovascular tissues, yet may also reflect a direct action on blood vessels. A few studies have 
investigated direct effects of SGLT2 inhibitors on cardiovascular tissues, with canagliflozin and phlorizin reported 
to relax murine pulmonary, but not coronary arteries ex vivo18. Furthermore, empagliflozin has been reported 
to improve the reduced viability of human umbilical vein endothelial cells (HUVECs) cultured in high glucose 
concentrations17, without altering basal HUVEC proliferation14. It therefore remains uncertain whether SGLT2 
inhibitors have beneficial direct effects on blood vessels.
We and others have recently demonstrated that clinically-relevant concentrations of canagliflozin, but not 
dapagliflozin or empagliflozin, activate AMP-activated protein kinase (AMPK) in immortalised cell lines and 
murine hepatocytes19,20. Furthermore, canagliflozin activated hepatic AMPK in vivo in mice19. Activation 
of AMPK by canagliflozin was associated with inhibition of complex I of the mitochondrial respiratory chain 
and increased ADP:ATP ratios19, suggesting that canagliflozin activated AMPK through the canonical pathway 
whereby reduced ATP and increased AMP (or ADP) allosterically activate AMPK, leading to activating phos-
phorylation of AMPK at Thr172 on the catalytic α subunit by liver kinase B1 (LKB1)21,22. Clinically-relevant 
concentrations of dapagliflozin have recently been reported to stimulate AMPK Thr172 phosphorylation 
in lipopolysaccharide-stimulated mouse cardiofibroblasts23. AMPK is a principal regulator of cellular and 
whole-body metabolism, yet numerous studies demonstrate that AMPK also regulates multiple pathways in car-
diovascular tissues that promote vascular health and inhibit vascular pathology, promoting anti-inflammatory 
and anti-atherogenic actions in blood vessels22. AMPK activation has been demonstrated to suppress palmitate- 
and TNFα-stimulated NFκB activity in human endothelial cells24, likely due to reduced IKKβ activity25. 
Furthermore, AMPK-dependent inhibition of adhesion molecule and MCP-1 expression has also been described 
in human endothelial cells25,26. Furthermore, we have previously demonstrated that direct activation of AMPK 
with A769662 inhibits IL-1β signalling in murine 3T3-L1 adipocytes and embryonic fibroblasts, reducing IRAK4 
autophosphorylation, the phosphorylation of MKK4, JNK, IKK and NFκB translocation to the nucleus27.
Since we and others have identified anti-inflammatory actions of AMPK activation in vascular cells and sys-
temic delivery of SGLT2 inhibitors has been reported to impair vascular inflammatory signalling and reduce ath-
eroma in mice, we examined whether SGLT2 inhibitors influence AMPK activity to influence pro-inflammatory 
signalling pathways in cultured human endothelial cells.
Results
Canagliflozin stimulates AMPK in human endothelial cells. Stimulation of HUVECs with 10 μmol/l 
canagliflozin significantly stimulated AMPK activity 1.8-fold, similar to AMPK activity in HUVECs stimulated 
with the direct AMPK activator, A769662 (Fig. 1a). The extent of AMPK activation was further stimulated by 
increasing the canagliflozin concentration to 30 μmol/l, whereas stimulation of HUVECs with concentrations of 
dapagliflozin and empagliflozin up to 30 μmol/l had no effect on AMPK activity (Fig. 1a). Activation of AMPK 
activity was also observed with 10 μmol/l canagliflozin in human aortic endothelial cells (HAECs), whereas con-
centrations of empagliflozin up to 100 μmol/l had no effect, demonstrating that this effect was not limited to 
endothelial cells from particular blood vessels (Fig. 1b). Canagliflozin also stimulated AMPK within 30 min in 
human vascular smooth muscle cells (HAoVSMCs), as assessed by levels of phosphorylation of the AMPK sub-
strate acetyl CoA carboxylase (ACC), demonstrating that canagliflozin-stimulated AMPK activation occurs in 
multiple vascular cell types (Supplementary Figure S1). Therapeutic doses of canagliflozin reach a peak con-
centration of approximately 6–8 μmol/l in the plasma of people with diabetes and healthy individuals, whereas 
dapagliflozin and empagliflozin produce peak concentrations of approximately 1–2 μmol/l28–30. As 10 μmol/l 
canagliflozin and 1 μmol/l empagliflozin or dapagliflozin reflect therapeutically-relevant concentrations, these 
were used for subsequent experiments.
We have previously demonstrated that canagliflozin inhibits glucose uptake in mouse embryonic fibro-
blasts and HEK-293 cells19. Canagliflozin rapidly inhibited 2-deoxyglucose uptake by approximately 70% in 
HUVECs, whereas dapagliflozin caused a more modest inhibition of 2-deoxyglucose uptake (~25%) (Fig. 2a). 
Immunoreactive bands of approximately 60 kDa could be detected with anti-SGLT2 antibodies in HUVEC and 
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HAEC cell lysates that co-migrated with bands in the human embryonic kidney cell line HEK-293 and a mouse 
kidney membrane fraction (Fig. 2b). Despite this and the inhibition of 2-deoxyglucose uptake by canagliflozin 
and dapagliflozin, SGLT2 mRNA was undetectable in HAECs or HUVECs, as well in the human embryonic 
kidney cell line HEK-293, whereas SGLT2 mRNA was detectable in cDNA prepared from human kidney cortex 
(Table 1). Although canagliflozin and dapagliflozin are selective inhibitors of SGLT2, the concentrations used 
could also inhibit SGLT131.
Specific anti-SGLT1 immunoreactivity could not be demonstrated in lysates from HUVEC, HAEC and HEK-
293 cells or a mouse kidney membrane fraction, as several immunoreactive bands were detected with anti-SGLT1 
antibodies (Supplementary Figure S2). Similarly, SGLT1 mRNA was expressed at very low levels in HAECs, 
HUVECs or HEK-293 cells, yet showed significant expression in kidney cortex (Table 1). HUVEC proliferation 
was stimulated by increasing the concentration of MV2 supplement mix, which contains serum and growth fac-
tors, from 2.5% − 5% (v/v) (Fig. 2c). Despite the inhibition of 2-deoxyglucose uptake, however, incubation with 
canagliflozin, dapagliflozin or empagliflozin for 36 h had no effect on HUVEC proliferation in either concentra-
tion of supplement mix (Fig. 2c), although canagliflozin did modestly reduce HUVEC viability as assessed with 
a tetrazolium-based assay (Fig. 2d).
Canagliflozin inhibits IL-1β-stimulated secretion of MCP-1 and IL-6 in an AMPK-dependent 
manner, associated with reduced mRNA expression. Canagliflozin inhibited IL-1β-stimulated 
MCP-1 and IL-6 secretion by HUVECs to a similar extent to the inhibition by A769662 (Fig. 3a), whereas nei-
ther dapagliflozin nor empagliflozin had any effect, indicating that canagliflozin-stimulated AMPK activation 
Figure 1. Canagliflozin stimulates AMPK in human endothelial cells. (a) HUVECs were stimulated with 
A769662 (100 μmol/l, 30 min) or the indicated concentrations of canagliflozin, dapagliflozin or empagliflozin 
for 15 min and lysates prepared. (b) HAECs were stimulated with the indicated concentrations of canagliflozin, 
empagliflozin or A769662 for 30 min and lysates prepared. AMPK was immunoprecipitated from lysates 
and assayed for AMPK activity. Data shown represents AMPK activity (% vehicle) from three independent 
experiments. **p < 0.01; ***p < 0.001 vs vehicle (two-tail t-test).
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may underlie this anti-inflammatory action. The anti-inflammatory action of canagliflozin was not limited to 
HUVECs, as it also inhibited IL-1β-stimulated MCP-1 secretion in human aortic endothelial cells (HAECs) 
(Fig. 3b). Furthermore, the inhibitory effect of canagliflozin was likely to be AMPK-dependent, as infection 
of HAECs with adenoviruses expressing a dominant negative mutant AMPKα1 (Ad.AMPK-DN)32 attenuated 
the effect of canagliflozin and A769662 (Fig. 3b). Stimulation of AMPK was still observed after 6 h incuba-
tion with canagliflozin or A769662, as assessed by phosphorylation of the AMPK substrate ACC and infection 
with Ad.AMPK-DN markedly suppressed canagliflozin- and A769662-stimulated ACC phosphorylation 
(Supplementary Figure S3). Canagliflozin did not have a general effect on secretion, as canagliflozin had no effect 
Figure 2. Canagliflozin inhibits 2-deoxyglucose uptake in HUVECs without influencing cell proliferation. 
(a) HUVECs were preincubated in the presence or absence of canagliflozin (10 μmol/l) for the times indicated 
or dapagliflozin (10 μmol/l, 30 min) and 2-deoxyglucose uptake assessed. Data shown represents the mean 
2-deoxyglucose uptake relative to vehicle from three independent experiments. **p < 0.01, ***p < 0.001 
relative to vehicle (one-way ANOVA). (b) Cell lysates from HUVECs (2 independent lysates), HAECs (4 
independent lysates) and HEK-293 cells and mouse kidney membranes were resolved by SDS-PAGE and 
immunoblotted with anti-SGLT2 antibodies. The immunoblot shown has been cropped, with the full-length 
immunoblot shown in Supplementary Figure S7. (c,d) HUVECs were incubated in the presence or absence 
of canagliflozin, dapagliflozin or empagliflozin and (c) proliferation assessed in 2.5% (v/v) or 5% (v/v) MV2 
Supplement mix (serum) by BrdU incorporation or (d) viability assessed by MTS assay. Data shown represents 
the mean proliferation or viability relative to vehicle (in 5% MV2 supplement mix) from three independent 
experiments in each cae. ##p < 0.01 relative to vehicle (two-tailed t-test).
Sample Ct (TBP) Ct (SGLT1) SGLT1 2−ΔΔCt Ct (SGLT2) SGLT2 2−ΔΔCt
Human kidney cortex 25.00 22.68 1 17.73 1
HAEC 23.67 ± 0.39 34.65 ± 0.23 1.04 × 10−4 ± 0.22 × 10−4 ND ND
HUVEC 23.53 ± 0.12 34.24 ± 0.29 1.26 × 10−4 ± 0.28 × 10−4 ND ND
HEK-293 22.10 ± 0.16 30.89 ± 0.45 4.61 × 10−4 ± 0.94 × 10−4 ND ND
Table 1. Expression of SGLT2 and SGLT1 mRNA in human endothelial cells. Expression of SGLT2, SGLT1 
relative to TBP was assessed by qPCR in cDNA prepared from three independent cultures of HUVECs, 
HAECs and HEK-293 cells, using cDNA from human kidney cortex as a positive control. Data shown are the 
mean ± SEM Ct values and 2−ΔΔCt in each case, from three independent samples. ND = Not detected.
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Figure 3. Canagliflozin inhibits IL-1β-stimulated MCP-1 and IL-6 secretion in human endothelial cells. (a,c) 
HUVECs were stimulated with IL-1β (10 ng/ml) for (a) 6 h or (c) 24 h following preincubation in the presence 
or absence of canagliflozin (10 μmol/l, 15 min), dapagliflozin (1 μmol/l, 15 min), empagliflozin (1 μmol/l, 
15 min) or A769662 (100 μmol/l, 30 min) and conditioned medium collected. (b) HAECs were infected with 
100 pfu/cell Ad.null or Ad.AMPK-DN for 24 h and preincubated in the presence or absence of canagliflozin 
(10 μmol/l, 15 min) or A769662 (100 μmol/l, 30 min) prior to stimulation with IL-1β (10 ng/ml) for 6 h and 
conditioned medium collected. (a,b) MCP-1, (a) IL-6 or (c) endothelin-1 levels were assayed in conditioned 
medium by ELISA. Data shown represents the % IL-1β-stimulated MCP-1, IL-6 or endothelin-1 secretion 
from (a,c) three (b) four (Ad.null) or five (Ad.AMPK-DN) independent experiments. *p < 0.05, **p < 0.01, 
***p < 0.001 relative to IL-1β alone (ANOVA).
www.nature.com/scientificreports/
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on endothelin-1 secretion by HUVECs, which was not stimulated by IL-1β (Fig. 3c). Canagliflozin inhibited 
IL-1β-stimulated expression of MCP-1 and IL-6 mRNA in HAECs, suggesting that this may underlie, at least in 
part, the inhibition of IL-1β-stimulated MCP-1/IL-6 secretion (Fig. 4a,b). In contrast, incubation with A769662 
did not significantly inhibit expression of either MCP-1 or IL-6 mRNA, indicating that the effect of canagliflozin 
on MCP-1 or IL-6 mRNA expression is AMPK-independent.
Canagliflozin and AMPK activators inhibit IL-1β-stimulated U937 cell adhesion to endothelial 
cells without altering cell surface adhesion molecule levels. We have previously demonstrated that 
brief preincubation with AMPK activators inhibits TNFα-stimulated U937 promonocytic cell adhesion to and 
MCP-1 secretion by HAECs prior to any changes in cell surface adhesion molecule expression26,33. In agreement 
with this, neither canagliflozin nor A769662 inhibited IL-1β-stimulated cell surface expression of E-selectin, vas-
cular cell adhesion molecule-1 (VCAM-1) or intercellular adhesion molecule-1 (ICAM-1) (Fig. 4c–e), yet both 
canagliflozin and A769662 markedly inhibited IL-1β-stimulated U937 cell adhesion (Fig. 5a), without altering 
basal U937 cell adhesion.
A769662, but not canagliflozin inhibits rapid IL-1β-stimulated JNK phosphorylation. We 
have recently reported that A769662 inhibited IL-1β-stimulated JNK phosphorylation, IKK phosphoryl-
ation and p65 NFκB translocation to the nucleus in 3T3-L1 adipocytes and mouse embryonic fibroblasts in 
an AMPK-dependent manner27. We therefore investigated the role of JNK and NFκB in the inhibition of the 
actions of IL-1β. Incubation of HUVECs with the JNK-selective inhibitor SP600125 phenocopied the effect of 
Figure 4. Canagliflozin suppresses IL-1β-stimulated MCP-1 and IL-6 mRNA expression, without altering 
cell surface adhesion molecule levels in HAECs. HAECs were stimulated with (a,b) IL-1β (10ng/ml) for 6 h 
or (c,d,e) IL-1β (5 ng/ml) for 4 h following preincubation in the presence or absence of A769662 (30 min, 100 
μmol/l) or canagliflozin (15 min, 10 μmol/l). (a) MCP-1 or (b) IL-6 mRNA levels were analysed by qPCR and 
cell surface levels of (c) E-selectin, (d) ICAM-1 or (e) VCAM-1 were assessed by flow cytometry. Data shown 
represents (a, b) % IL-1β-stimulated mRNA expression normalised to TBP from four independent experiments 
or (c,d,e) % positively stained HAECs from three independent experiments. ***p < 0.001 relative to IL-1β alone 
(ANOVA).
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canagliflozin on U937 cell adhesion (Fig. 5a), without altering canagliflozin- or A769662-stimulated AMPK 
activity, as assessed by ACC phosphorylation, which remained elevated after 6 h stimulation (Fig. 5b). Despite 
this, neither canagliflozin nor A769662 had any significant effect on levels of phosphorylated JNK after 6 h stim-
ulation with IL-1β (Fig. 5b,c). In contrast to the lack of effect on levels of phosphorylated JNK after 6 h stim-
ulation with IL-1β, A769662 did inhibit the initial IL-1β-stimulated JNK phosphorylation within 15 min, yet 
canagliflozin had no effect (Fig. 6). Similarly, canagliflozin had no significant effect on IL-1β-stimulated JNK 
phosphorylation in HAoVSMCs and stimulation of HAoVSMCs with the alternative pro-inflammatory stimu-
lus angiotensin II had no effect on JNK phosphorylation (Supplementary Figure S1). Stimulation of HUVECs 
with an alternative direct AMPK activator, compound 991, which is reported to bind to the same site on AMPK 
as A76966234, markedly increased ACC phosphorylation in HUVECs and inhibited IL-1β-stimulated JNK 
phosphorylation (Supplementary Figure S4). Conversely, infection of HAECs with Ad.AMPK-DN markedly 
increased IL-1β-stimulated phosphorylation of JNK (Supplementary Figure S4). Despite our previous observa-
tion that A769662 inhibited NFκB signalling in 3T3-L1 adipocytes and mouse embryonic fibroblasts27, neither 
Figure 5. Canagliflozin inhibits IL-1β-stimulated adhesion of U937 cells to HUVECs. HUVECs were 
stimulated in the presence or absence of SP600125 (60 min, 30 μmol/l), A769662 (30 min, 100 μmol/l) or 
canagliflozin (15 min, 10 μmol/l) prior to stimulation with IL-1β (10 ng/ml) for 6 h. and (a) U937 cell adhesion 
assessed or (b) lysates prepared. (a) Data shown represents the % IL-1β-stimulated U937 cell adhesion from 
three independent experiments, with 8 fields of cells examined in each technical replicate. Representative 
micrographs are shown in Supplementary Figure S8. (b,c) HUVEC lysates were immunoblotted with the 
antibodies indicated. (b) Representative images are shown and have been cropped, with the full-length 
immunoblots shown in Supplementary Figure S9. (c) Densitometric analysis of JNK (p54) phosphorylation 
normalised to respective total JNK from four (canagliflozin) or two (A769662) independent experiments. 
***p < 0.001 relative to IL-1β alone (ANOVA).
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A769662 nor canagliflozin had any effect on IL-1β-stimulated IKK phosphorylation (Fig. 6) or p65 NFκB trans-
location to the nucleus after 15 min in HUVECs (Supplementary Figure S5), and canagliflozin had no effect 
on IL-1β-stimulated IKK or IκBα phosphorylation or degradation of IRAK1 or IκBα at any time point exam-
ined (Fig. 7). Increasing the canagliflozin concentration to 30 μmol/l did, however, cause a modest yet signif-
icant reduction in early (5 min) IL-1β-stimulated IKK and JNK phosphorylation, as well as IκB degradation 
(Supplementary Figure S6).
Discussion
The principal finding of this study is that clinically-relevant concentrations of canagliflozin, but not dapagliflozin 
or empagliflozin inhibit IL-1β-stimulated secretion of the key pro-inflammatory cytokine IL-6 and chemokine 
MCP-1 in cultured human endothelial cells. Furthermore, we show that this effect of canagliflozin is, at least 
in part, AMPK-dependent and associated with reduced adhesion of pro-monocytic cells. However, canagli-
flozin has no significant effect on IL-1β-stimulated JNK or NFκB signalling, suggesting the effect on chemokine/
cytokine secretion and monocyte adhesion is independent of early pro-inflammatory signalling. Comparison of 
the effects of canagliflozin with the direct AMPK activator, A769662, also suggested that canagliflozin inhibits 
IL-1β-stimulated MCP-1 and IL-6 gene expression in an AMPK-independent manner. These data suggest that 
canagliflozin could suppress vascular inflammatory signalling, which is associated with the development of car-
diovascular disease.
The finding that only canagliflozin of the three SGLT2 inhibitors examined activated AMPK in cultured 
human endothelial cells is in agreement with our and others’ previously published reports in immortalised cell 
lines and murine hepatocytes19,20. Furthermore, we show that the same clinically-relevant concentration of cana-
gliflozin activates AMPK in HAoVSMCs. We have previously reported that canagliflozin inhibits complex I in the 
mitochondrial respiratory chain, which is likely to underlie the AMPK activation due to increased AMP:ATP19. 
In the current study we did not determine mitochondrial function, yet canagliflozin did modestly reduce HUVEC 
viability without altering proliferation as assessed with an MTS-based measurement that reflects levels of NAD(P)
H produced by dehydrogenase enzymes in metabolically active cells35, such that the canagliflozin-mediated 
reduction may indicate reduced mitochondrial dehydrogenase activity. Canagliflozin, and to a lesser extent 
dapagliflozin, inhibited HUVEC 2-deoxyglucose uptake, as we have previously observed in HEK-293 cells and 
mouse embryonic fibroblasts19. It is feasible that reduced glucose uptake could impair ATP synthesis and thereby 
Figure 6. A769662 but not canagliflozin inhibits early IL-1β-stimulated JNK phosphorylation. HUVECs were 
incubated in the presence or absence of canagliflozin (10 μmol/l, 15 min) or A769662 (100 μmol/l, 30 min) 
prior to stimulation with IL-1β (10 ng/ml, 15 min) and lysates prepared. Lysate proteins were resolved by 
SDS-PAGE and subjected to immunoblotting with the antibodies indicated. (a) Representative immunoblots, 
repeated on two further occasions with similar results are shown and have been cropped, with the full-length 
immunoblots shown in Supplementary Figure S10. (b,c) Densitometric analysis of (b) JNK (p54) and (c) IKK 
phosphorylation normalised to respective total levels from three independent experiments. **p < 0.01 vs 
absence of A769662 (ANOVA).
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contribute to the activation of AMPK by canagliflozin. Importantly, the medium (MV2) used in the majority of 
the experiments described also contains amino acids, which would be predicted to provide an alternative source 
of ATP in the event of inhibited glucose transport and phosphorylation. It therefore remains unclear whether 
Figure 7. Effect of 10 μmol/l canagliflozin on initial IL-1β pro-inflammatory signalling pathways. HUVECs 
were incubated for 15 min in the presence or absence of canagliflozin (10 μmol/l) prior to stimulation with 
IL-1β (10 ng/ml) for the times indicated and lysates prepared. Lysate proteins were resolved by SDS-PAGE and 
subjected to immunoblotting with the antibodies indicated. (a) Representative images are shown and have been 
cropped, with the full-length immunoblots shown in Supplementary Figure S11. (b–e) Densitometric analysis 
of (b) IRAK1, (d) IκB relative to GAPDH (% vehicle) or (c) IKK, (e) JNK (p54) phosphorylation (% 15 min IL-
1β-stimulated) normalised to respective total levels from three independent experiments.
www.nature.com/scientificreports/
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reduced glycolytic flux from glucose synergises with the inhibition of mitochondrial complex I that we have 
previously reported19 to impair ATP production and stimulate AMPK in response to canagliflozin in endothelial 
cells.
Although canagliflozin and dapagliflozin are selective inhibitors of SGLT2, the concentrations used could also 
inhibit SGLT131. In agreement with previous studies in human coronary or pulmonary artery endothelial cells18, 
SGLT2 mRNAs were expressed at undetectable levels in HUVECs and HAECs. Despite the lack of SGLT2 mRNA, 
immunoreactive bands of approximately 60 kDa were detected with anti-SGLT2 antibodies in endothelial cell 
lysates that co-migrated with a band in mouse kidney membranes, so it remains uncertain whether SGLT2 pro-
tein is present in human endothelial cells and underlies the inhibition of 2-deoxyglucose uptake by canagliflozin. 
SGLT1 mRNAs were expressed at very low levels in HUVECs and HAECs, similar to a previous report36, yet we 
were unable to detect SGLT1 protein by immunoblotting, unlike a previous study in HUVECs37. The inhibition of 
2-deoxyglucose uptake in HUVECs by 10 μmol/l canagliflozin may therefore be due to inhibition of a facilitative 
glucose transporter, as has been suggested before in a rat skeletal muscle cell line38.
Two recent studies have indicated that dapagliflozin may also stimulate AMPK activity. Administration of 
dapagliflozin for eight weeks increased cardiac AMPK Thr172 phosphorylation in lipodystrophic seipin knockout 
mice39 and stimulation of murine LPS-stimulated cardiofibroblasts with 0.4 μmol/l dapagliflozin for 16 h stimu-
lated AMPK phosphorylation, associated with reduced intracellular NLRP3 inflammasome and TNFα levels23. 
As these latter effects were mimicked by A769662 and inhibited by compound C, the authors argue the effect of 
dapagliflozin is AMPK-mediated, although it should be noted that compound C inhibits several other protein 
kinases with greater efficacy than AMPK40. In the current study, 0.3 μmol/l dapagliflozin had no effect on AMPK 
activity in HUVECs, suggesting the discrepancy between our study and that of Ye and colleagues may either 
reflect a tissue-specific effect, the LPS-stimulated background utilised by Ye and colleagues, in which AMPK 
activity is inhibited, or may be due to the markedly different incubation times with SGLT2 inhibitor used.
Several lines of evidence suggest that the marked inhibition of MCP-1 secretion by canagliflozin is 
AMPK-dependent. Firstly, the inhibition was mimicked by the direct AMPK activator, A769662 and secondly, 
of the three SGLT2 inhibitors examined, only canagliflozin activated AMPK and only canagliflozin reduced 
IL-1β-stimulated MCP-1 secretion in both HUVECs and HAECs. Finally, as the canagliflozin-mediated inhi-
bition was attenuated by infection with Ad.AMPK-DN, the inhibitory action of canagliflozin on chemokine/
cytokine secretion is at least partially AMPK dependent. In previous studies, we have reported that short-term 
incubation with AICAR, which is converted to the AMP mimetic ZMP within cells41, inhibited TNFα-stimulated 
MCP-1 secretion by and U937 cell adhesion to HAECs in an AMPK-dependent manner, without altering cell 
surface adhesion molecule expression26. In the current study, stimulation with canagliflozin or A769662 inhibited 
IL-1β-stimulated U937 cell adhesion without altering cell surface adhesion molecule levels in a similar manner. 
This further supports an AMPK-dependent mechanism for the inhibition of MCP-1 secretion by canagliflozin 
that is likely to underlie the inhibition of monocyte adhesion without altering levels of cell surface adhesion 
molecules.
Despite the similar effects of A769662 and canagliflozin on endothelial cell AMPK activity, IL-1β-stimulated 
MCP-1/IL-6 secretion, U937 cell adhesion and cell surface adhesion molecule expression, there were some dif-
ferential actions of canagliflozin and A769662 upstream of the effect on MCP-1 and IL-6 secretion. Canagliflozin 
inhibited IL-1β-stimulated expression of both MCP-1 and IL-6 mRNA, whereas A769662 had no effect. Given 
the similar stimulation of AMPK by both compounds, it seems likely, therefore, that this effect of canagliflozin 
is AMPK-independent. In contrast, A769662 and compound 991 inhibited IL-1β-stimulated JNK phosphoryl-
ation, whereas canagliflozin only altered JNK phosphorylation at high concentrations, suggesting that AMPK 
activation is not sufficient to inhibit JNK phosphorylation. The differential effects of canagliflozin and A769662 
may also reflect their different modes of activating AMPK. Whereas canagliflozin increases ADP:ATP, reducing 
cellular energy charge and allosterically activating AMPK by the canonical mechanism, A769662 and compound 
991 directly activate AMPK complexes containing the β1 non-catalytic subunit isoform without altering cellular 
adenine nucleotide ratios4,19–22. As a consequence, it would be predicted that canagliflozin activates all AMPK 
complexes as well as inhibiting ATP synthesis and thereby other pathways that are sensitive to ATP or AMP 
concentrations, whereas A769662 (and compound 991) only activate AMPK complexes containing β1 without 
altering cellular energy charge directly. Indeed, AMPKβ1 and AMPKβ2 have been reported to have markedly dif-
ferent subcellular localisation in HUVECs42, suggesting the potential for differential roles. Stimulation of different 
pools of AMPK and parallel effects on AMPK-independent pathways may, therefore underlie the different effects 
of canagliflozin compared to A769662 and compound 991 upstream of IL-1β-stimulated monocyte adhesion and 
secretion of MCP-1 and IL-6.
Given the widely-reported anti-inflammatory actions of AMPK activation in response to several proinflam-
matory cytokines in endothelial cells22, it is tempting to speculate that there is a common anti-inflammatory 
mechanism of action for AMPK activators, yet cytokines such as IL-1β, TNFα and IL-6 employ different sig-
nalling mechanisms, with various degrees of shared intermediates. Multiple mechanisms have been described 
by which AMPK may inhibit NFκB activation25,43, and we have previously reported in murine 3T3-L1 adipo-
cytes and embryonic fibroblasts that A769662 inhibits IL-1β-stimulated JNK and NFκB activation, yet had little 
effect on TNFα-stimulated JNK phosphorylation27. Furthermore, the inhibition by AMPK was associated with 
inhibition of IRAK4 autophosphorylation, arguing for an inhibitory effect of AMPK on the first steps of IL-1β 
signalling27. In the current study, neither A769662 nor canagliflozin had any effect on IL-1β-stimulated IKKβ 
phosphorylation or translocation of p65 NFκB to the nucleus, which was surprising given the marked effect of 
both compounds on MCP-1 secretion and key role NFκB activation has in the stimulation of MCP-1 gene expres-
sion. This further indicates that the mechanism by which AMPK activation inhibits IL-6 and MCP-1 secretion in 
endothelial cells is independent of effects on NFκB signalling and gene expression.
www.nature.com/scientificreports/
1 1SCIentIfIC RepoRts |  (2018) 8:5276  | DOI:10.1038/s41598-018-23420-4
As AMPK activation inhibits the mechanistic target of rapamycin complex 1 (mTORC1), which is a key regu-
lator of translation, this could represent a common target that explains the inhibition of MCP-1 and IL-6 secretion 
by both canagliflozin and A769662 in the absence of consistent effects on mRNA expression. Indeed, inhibition of 
mTORC1 has been reported to inhibit IL-6 secretion44,45, yet without affecting basal or TNFα-stimulated MCP-1 
secretion44, suggesting that AMPK-mediated mTORC1 suppression is unlikely to mediate the effects observed 
in this study. AMPK activation has also been reported to influence endothelial endocytosis46, yet, to our knowl-
edge, there are no reports of AMPK activation having any direct effect on the secretory pathway in endothelial 
cells. Given that we have also shown that AMPK activation inhibits IL-6-stimulated activation of STAT (signal 
transducer and activator of transcription) transcription factors27,47, likely to be mediated by AMPK-mediated 
phosphorylation and inhibition of Janus kinase 147, it is entirely likely that AMPK activation inhibits multiple 
pro-inflammatory pathways by multiple mechanisms that are cell-specific, such that care should be taken when 
examining the effects of AMPK activation on pro-inflammatory signalling in different tissues and species.
Previous studies have reported that systemic administration of the SGLT2 inhibitors empagliflozin, ipragli-
flozin or luseogliflozin decreases pro-inflammatory IL-6, MCP-1 and ICAM-1 gene expression in blood vessels 
of rodent models of diabetes13,15–17 and canagliflozin administration inhibits inflammation in metabolic tissues 
of high fat diet-fed mice48. The reduced vascular inflammatory signalling observed with other SGLT2 inhibitors 
could be direct, but may also be secondary to changes in blood glucose concentrations, blood pressure and the 
effects on metabolic tissues such as the liver or adipose tissue over time. To our knowledge, no previous study has 
examined the direct actions of SGLT2 inhibitors on indices of vascular inflammation, such that our data suggests 
canagliflozin alone among the three SGLT2 inhibitors we examined has the potential to have a direct effect on 
vascular cells. It does remain possible, however, that prolonged incubation, rather than the acute stimulations we 
have used, of human endothelial cells with dapagliflozin or empagliflozin may inhibit pro-inflammatory stimuli 
or indeed activate AMPK.
In summary, canagliflozin inhibits IL-1β-stimulated secretion of the key pro-inflammatory, pro-atherogenic 
mediators MCP-1 and IL-6 in an AMPK-dependent manner, yet the precise mechanism(s) underlying this 
remains elusive. These data further suggest that clinically-relevant concentrations of canagliflozin have the poten-
tial to directly influence blood vessels in people with type 2 diabetes as well as lower blood glucose concentrations. 
It is tempting to speculate that the anti-inflammatory actions of canagliflozin we have identified could have an 
anti-atherogenic action in blood vessels, yet more research is required to examine the extent to which these might 
contribute to their beneficial cardiovascular actions in people with type 2 diabetes.
Materials and Methods
Materials. Adenoviruses expressing c-myc-tagged dominant negative mutant AMPKα1 (Ad.AMPK-DN) and 
control adenoviruses (Ad.null) have been described previously32, and were a generous gift from Dr F. Foufelle, 
Centre Biomédical des Cordeliers, Paris. Kidney cortex cDNA was prepared by Dr. Dominik Skiba, University 
of Glasgow, UK from the healthy margin of renal tumours obtained through the NHSGCC Biorepository and 
Pathology Service Tissue Resource (approved by West of Scotland Research Ethics Services No 10/S0704/60). 
Canagliflozin, dapagliflozin and empagliflozin were obtained from Selleckchem (Newmarket, UK). A769662 
was obtained from Abcam (Cambridge, UK). [γ-32P]-ATP was obtained from Perkin Elmer (Buckinghamshire, 
UK). SAMS peptide was obtained from GL Biochem Ltd (Shanghai, China). SP600125 was from Bio-Techne 
(Abingdon, UK). Recombinant human IL-1β and Quantikine ELISA kits for human endothelin-1, IL-6 and 
MCP-1 were obtained from R&D Systems (Abingdon, UK). Phycoerythrin-conjugated anti-ICAM1 (#555512), 
anti-VCAM-1 (#561679) and anti-E-selectin (#550040) antibodies were from BD Transduction Labs (Oxford, 
UK). Rabbit anti-phospho-acetyl CoA carboxylase (ACC) Ser79 (#3661), anti-ACC (#3676), anti-phospho-JNK 
Thr183/Tyr185 (#4668), anti-JNK (#9252), anti-phospho-IκBα Ser32 (#2859), anti-phospho-IKKα/β Ser176/
Ser177 (#2078), anti-IKKβ (#8943), anti-IRAK1 (#4504), anti-α-tubulin (#2125) and mouse anti-IκBα (#4814) 
antibodies were from New England Biolabs (Hitchin, Hertfordshire, UK). Mouse anti-GAPDH was obtained 
from Ambion (AM4300) (Cambridge, UK). Goat anti-SGLT2 (sc-47402) antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Sheep anti-AMPKα1 and anti-AMPKα2 antibodies for immunopre-
cipitation kinase assays have been described before49 and were a kind gift from Prof. D. G. Hardie, University 
of Dundee (Dundee, UK). Donkey Infrared dye-labelled secondary antibodies were from LI-Cor Biosciences 
(Cambridge, UK). CellTiter 96® AQueous One solution was purchased from Promega (Southampton, UK). BrdU 
cell proliferation assay kits were obtained from Millipore (Watford, UK). All other reagents were from sources 
described previously26,27,50.
Cell culture. Human umbilical vein endothelial cells (HUVECs) and aortic endothelial cells (HAECs) were 
cultured in MV2 medium (Promocell, Heidelberg, Germany) and used for experiments between passages 3 and 
6 as described previously50. HEK-293 cells were cultured in DMEM, supplemented with 10% (v/v) foetal calf 
serum, 1 mmol/l pyruvate and 2 mmol/l L-glutamine as described previously19. U-937 pro-monocytic cells were 
grown in RPMI 1640 medium, supplemented with 10% (v/v) foetal calf serum and 2 mmol/l L-glutamine as 
described previously26,33.
Preparation of adenoviruses and infection of HAECs. Ad.AMPK-DN and Ad.null were propagated, 
purified and titred as described previously26. HAECs were infected with adenoviruses for 24 h in MV2 medium 
prior to experimentation.
Preparation of cell lysates, SDS PAGE and immunoblotting. HUVECs or HAECs were serum-starved 
in Medium 199 for 2 h prior to addition of SGLT2 inhibitors, AMPK activators or IL-1β. Cell lysates were prepared, 
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proteins resolved by SDS-PAGE and subjected to quantitative immunoblotting with the antibodies indicated as 
described previously27,50. Immunolabelled proteins were visualized using infrared dye-labelled secondary antibodies 
and an Odyssey Sa infrared imaging system (LiCor Biosciences UK Ltd, Cambridge, UK). Band density was quantitated 
with Image J software.
Preparation of cell membrane fractions. Mouse kidneys were homogenized in 5 vol HES buffer 
(20 mmol/l Na HEPES-NaOH (pH 7.4), 1 mmol/l EDTA, 250 mmol/l sucrose; Roche complete protease inhibitor 
cocktail) with a Dounce homogenizer and centrifuged (7,050 × g, 20 min, 4 °C). The pellet was resuspended in 
HES buffer and layered on top of buffer containing 1.12 mol/l sucrose, prior to centrifugation in a swing-out 
rotor (25,000 × g, 60 min, 4 °C). Membranes were collected from the interface of the sucrose layer, diluted in HES 
buffer and centrifuged (150,000 × g, 60 min, 4 °C). The resultant plasma membrane-rich pellet was re-suspended 
in 0.2 ml HES buffer.
Immunoprecipitation and assay of AMPK activity. AMPK was immunoprecipitated from cell lysates 
using a mixture of sheep anti-AMPKα1 and anti-AMPKα2 antibodies and assayed using the SAMS substrate 
peptide as previously described27,50.
HUVEC proliferation assay. HUVECs (2 × 104 cells/well) were allowed to attach to 96-well plates for 4 h 
in MV2 medium containing 2.5% or 5% (v/v) MV2 Supplement Mix (Promocell C-39226) containing serum 
and growth factors and subsequently incubated in the same medium with DMSO (vehicle) or SGLT2 inhibitors 
for 12 h. BrdU reagent was then added and cells further incubated for 24 h. BrdU incorporation was assessed by 
measuring A485/520 on a BMG Labtech FLUOstar Optima spectrophotometer microplate reader.
HUVEC viability assay. HUVECs (2 × 104 cells/well) were allowed to attach to 96-well plates for 4 h in 
MV2 medium containing 5% (v/v) MV2 Supplement Mix and subsequently incubated in the same medium with 
DMSO (vehicle) or SGLT2 inhibitors for 24 h. CellTiter 96® AQueous One Solution Aqueous Cell solution was 
added 1.5 h prior to the end of incubation, at which point A485 was measured on a BMG Labtech FLUOstar 
Optima spectrophotometer microplate reader.
Analysis of MCP-1, IL-6 and endothelin-1 secretion. Confluent monolayers of HUVECs or HAECs 
in 6-well plates were washed into medium 199 and preincubated in the presence or absence of A769662 or 
SGLT2 inhibitors for 30 min or 15 min respectively prior to stimulation with 10 ng/ml IL-1β for 6 h (MCP-1 and 
IL-6 secretion) or 24 h (endothelin-1 secretion) and the culture medium transferred to microcentrifuge tubes. 
Conditioned media were centrifuged (3,130 × g, 20 min, 4 °C and MCP-1, IL-6 or endothelin-1 levels assayed in 
supernatants using Quantikine ELISA kits as per the manufacturer’s instructions.
2-deoxyglucose uptake assay. HUVECs were incubated in serum-free Medium 199 for 2 hours, the 
media removed and replaced with Krebs-Ringer phosphate buffer (KRP) (130 mmol/l NaCl, 4.8 mmol/l KCl, 
5 mmol/l NaH2PO4, 1.25 mmol/l MgSO4, 1.25 mmol/l CaCl2) containing 5 mmol/l glucose for 45 min. HUVECs 
were then incubated in glucose-free KRP in the presence or absence of SGLT2 inhibitors prior to the addition of 
2-[3H]-deoxyglucose (50 µmol/l, 1 µCi/ml). Cytochalasin B-sensitive 2-deoxyglucose uptake was measured over 
10 min as described previously19.
U937 cell adhesion assay. HUVECs were grown to confluence on 24-well tissue culture plates and 
pre-incubated in the presence or absence of A769662, canagliflozin and/or SP600125 as indicated. Cells were 
subsequently stimulated in the presence or absence of 10 ng/ml IL-1β for 6 h. The medium was subsequently 
aspirated and HUVEC monolayers washed thoroughly with serum-free RPMI 1640 to remove activators/inhib-
itors prior to overlay with 1 × 105 U937 cells/well in serum-free RPMI 1640. The cells were allowed to adhere for 
1 h at 37 °C, the medium removed, and monolayers washed three times with serum-free RPMI 1640 to remove 
non-adherent U937 cells. Cells were fixed in PBS supplemented with 4% (w/v) paraformaldehyde and 5% (w/v) 
sucrose, and the number of adhered U937 cells per field of confluent HUVECs counted, with the investigator 
blinded as to the experimental conditions, on a Zeiss Axiovert 135 microscope with a X5 objective.
RNA extraction and gene expression analysis. RNA was extracted from HAECs, HUVECs or 
HEK-293 cells using an RNeasy kit (Qiagen). Between 400–1000 ng of RNA was reverse-transcribed using the 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qPCR was performed with an Applied 
Biosystems ABI-PRISM 7900HT Sequence Detection System. Gene expression was normalized to TATA bind-
ing protein (TBP) using QPCR master mix (Applied Biosystems) and the following TaqMan® Gene Expression 
Assays (Applied Biosystems): TBP (Hs00427620_m1), SLC5A1 (SGLT1, Hs01573793_m1), SLC5A2 (SGLT2, 
Hs00894642_m1), IL6 (Hs00174131_m1) and CCL2 (MCP-1, Hs00234140_m1).
Assessment of cell surface E-Selectin, VCAM-1 and ICAM-1 levels. Confluent HAECs were incu-
bated in the presence or absence of canagliflozin (10 μmol/l, 15 min) or A769662 (100 μmol/l, 30 min) prior 
to stimulation with 5 ng/ml IL-1β for 4 h. Cells were gently dislodged by trypsinisation, neutralised with com-
plete MV2 culture medium and re-suspended in PBS supplemented with 1% (w/v) BSA (PBS-BSA). Cells 
were then incubated with saturating concentrations of phycoerythrin-labelled anti-ICAM-1, anti-VCAM-1 or 
anti-E-Selectin antibodies for 1 h, washed three times and resuspended in PBS-BSA. Cell surface adhesion mole-
cule expression was evaluated in 104 cells by flow cytometry using a FACSCalibur flow cytometer (BD Bioscience, 
Oxford, UK).
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Statistics. Results are expressed as mean ± SEM. Statistically significant differences were determined using a 
two-tail t-test, or ANOVA where appropriate, with p < 0.05 as significant using GraphPad Prism software.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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